Fundraising FoxMountain Group Capital — 2015 Investments
2 investments dated 2015 · listed companies and verified rows first · show all
G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
BiotechResearch Triangle Park, US
Jay Strum(Executive Officer)Norman Sharpless(Director)Mark A. Velleca(Executive Officer, Director)inThomas K Laundon(Executive Officer)Timothy Sullivan(Director)Gregory Mossinghoff(Executive Officer)
Co-investorsLumira VenturesRA CapitalSolasta VenturesHatteras Venture Partners
Lineagen provides genetic testing and optical genome mapping services for clinical diagnosis and research applications.
BiotechDigital HealthHealthtechMedical DevicesSalt Lake City, US
Gayland Moffat(Executive Officer)Michael S. Paul(Executive Officer, Director)
BoardMichael Fitzgerald(Director)Fred A. Middleton(Director)Mary C. Tanner(Director)Michael Walsh(Director)
Co-investorsMESA VERDE VENTURE PARTNERSHealthQuest Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.